Although Attention Deficit Hyperactivity Disorder (ADHD) is associated with an increased risk of substance use disorder (SUD), existing literature on how SUD interacts with ADHD outcomes is limited. This presentation will discuss the interaction between SUD among individuals with ADHD. The presentation will summarize the results of the new research conducted in that area. It will discuss the association between overall functioning of patients with ADHD who reported using substances. In addition, It will help participants understand the association between heavy cannabis use and ADHD outcomes and functioning.
Dr. Joseph Sadek, MD, MBA, B.Sc. Pharm, FRCPC, DABPN is an Associate Professor of Psychiatry at Dalhousie University, the clinical and academic leader, NSH acute care and the director of the Atlantic ADHD center in NS.
He served as the VP of CADDRA and currently a member of CADDRA advisory board.
Dr. Sadek is the chair of the Education committee of the Canadian Psychiatric Association and the chair of the senate Appeal Subcommittee of Dalhousie University.
He completed his psychiatry residency training at Dalhousie University in 2004 and his psychopharmacology research training and GCSRT at Harvard University.
Dr.Sadek is the author of 5 books “Clinician’s Guide to ADH (2013), Adult ADHD comorbidities” (Springer, 2016) and child and Adolescents ADHD comorbidities” (2018), Suicide Risk Assessment (2019) and Clinician’s Guide to psychopharmacology (2021). Dr. Sadek received several awards and grants. Latest from the Government of NS House of Assembly in 2019.
He served as the provincial chair the Nova Scotia Suicide Prevention Initiative and member of the provincial education and training committee.
Dr. Sadek is internationally recognized for his expertise in diagnosis and management of mental disorders including ADHD.